Abstract
Fifty to sixty percent of patients infected with hepatitis C virus (HCV) have treatment success with pegylated interferon plus ribavirin. Low-dose interferon without ribavirin is currently being evaluated as maintenance therapy for suppressing viral replication and retarding liver-fibrosis progression to prevent complications of advanced liver disease and to lengthen survival. In this randomized trial, investigators assessed the ability of interferon alfa-2a to lengthen complication-free survival in HCV-positive patients with compensated cirrhosis. From …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
